Proneuropeptide Y and neuropeptide Y metabolites in healthy volunteers and patients with a pheochromocytoma or paraganglioma.
Fiche du document
1 septembre 2022
- doi: 10.1016/j.cca.2022.07.018
- issn: 0009-8981
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.cca.2022.07.018
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/35905838
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1873-3492
Ce document est lié à :
info:eu-repo/grantAgreement/OTHER//Ligue suisse contre le cancer, KLS-4283-08-2017///
Ce document est lié à :
info:eu-repo/grantAgreement/OTHER//Bryn Turner-Samuels Foundation///
Ce document est lié à :
info:eu-repo/grantAgreement/OTHER//Clinical Research Priority Program of the University of Zurich///
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_569E60EE2BE03
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
Neuropeptide tyrosine NPY (Neuropeptide)Citer ce document
P.J. Eugster et al., « Proneuropeptide Y and neuropeptide Y metabolites in healthy volunteers and patients with a pheochromocytoma or paraganglioma. », Serveur académique Lausannois, ID : 10.1016/j.cca.2022.07.018
Métriques
Partage / Export
Résumé
Neuropeptide Y (NPY1-36) is a vasoconstrictor peptide co-secreted with catecholamines by sympathetic nerves, the adrenal medulla, and neoplasms such as pheochromocytomas and paragangliomas (PPGLs). It is produced by the intracellular cleavage of proNPY and metabolized into multiple fragments with distinct biological activities. NPY immunoassays for PPGL have a diagnostic sensitivity ranging from 33 to 100%, depending on the antibody used. We have validated a multiplex micro-UHPLC-MS/MS assay for the specific and sensitive quantification of proNPY, NPY1-39, NPY1-37, NPY1-36, NPY2-36, NPY3-36, NPY1-35, NPY3-35, and the C-flanking peptide of NPY (CPON) (collectively termed NPYs), and determined the NPYs reference intervals and concentrations in 32 PPGL patients before, during, and after surgery. Depending on the peptide measured, NPYs were above the upper reference limit (URL) in 20% to 67% of patients, whereas plasma free metanephrine and normetanephrine, the gold standard for PPGL, were above the URL in 40% and 87% of patients, respectively. Age, sex, tachycardia, and tumor localization were not correlated with NPYs. Plasma free metanephrines performed better than NPYs in the detection of PPGL, but NPYs may be a substitute for an early diagnosis of PPGL for patients that suffer from severe kidney impairment or receiving treatments that interfere with catecholamine reuptake.